MRCA Combined With Zero-Contrast IVUS-Guided PCI in a Patient With NSTE-ACS and Severe Contrast Allergy Authors: Huan Wang, Yan Wu, Zhijie Jian, Yongbai Luo Published: 2026 ABSTRACT AbstractBackgroundThe management of acute coronary syndrome in patients with severe hypersensitivity reactions to iodine-based contrast media (ICM) remains a considerable clinical challenge, particularly when coronary anatomy is undetermined.Case SummaryA 50-year-old man with non–ST-segment elevation acute coronary syndrome and severe hypersensitivity reactions to ICM was referred for revascularization without coronary anatomic information. Magnetic resonance coronary angiography (MRCA) and zero-contrast intravascular ultrasound (IVUS) were integrated for the first time to evaluate coronary artery lesions and guide percutaneous coronary intervention.DiscussionThis case demonstrates that combining MRCA with IVUS-guided percutaneous coronary intervention presents a promising direction for managing patients with coronary artery disease who experience hypersensitivity reactions to ICM. This is especially beneficial for high-risk patients who require revascularization.Take-Home MessageMultimodality imaging strategy, which integrates MRCA and IVUS, provides a viable solution to such clinical challenges, thereby enabling revascularization in patients with coronary artery disease and specific contraindications to conventional imaging.Key words: acute coronary syndrome, contrast agent allergy, intravascular ultrasound, magnetic resonance coronary angiography, percutaneous coronary intervention Integrating Magnetic Resonance Coronary Angiography With Intravascular Ultrasound to Guide Percutaneous Coronary Intervention in a Patient With NSTE-ACS and Severe Contrast Allergy (A) Volume rendering image demonstrating normal coronary artery origin and distribution. (B) Curved planar reformation revealing significant stenosis in the proximal LAD artery (red arrow). (C) IVUS longitudinal view demonstrating extensive fibrofatty plaque from mid-LAD artery to the ostium. (D) Minimum stent area of 6.74 mm2 in the distal LAD artery with complete stent expansion and apposition. (E) The stent area of 8.95 mm2 in the MLA site of the LAD artery. (F) MSA of 15.42 mm2 in the LM with excellent stent expansion. IVUS = intravascular ultrasound; LAD = left anterior descending; LM = left main coronary artery; MRCA = magnetic resonance coronary angiography; MLA = minimum lumen area; MSA = minimum stent area; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention. History of Present Illness A 50-year-old man was referred for non–ST-segment elevation acute coronary syndrome with previous severe hypersensitivity reactions to iodine-based contrast media (ICM). One month before admission, the patient was scheduled for coronary angiography in another hospital. However, he experienced dyspnea and facial edema during ICM injection for right radial artery angiography, which was attributed to severe contrast agent allergy. The coronary angiography was terminated without clarifying the images of the coronary arteries. One week ago, owing to worsening exertional chest pain and dyspnea, he was referred for evaluation for potential zero-contrast percutaneous coronary intervention (PCI) at our institution. His blood pressure was 134/84 mm Hg with a heart rate of 79 beats/min. He was hemodynamically stable, and physical examination findings were unremarkable. Laboratory analysis was notable for elevation in high-sensitivity troponin T of 0.16 ng/mL and serum creatinine levels of 111 μmol/L. The treadmill exercise test (TET) showed ST-segment depression in leads II, III, aVF, V3 to V6, with ST-segment elevation in lead aVR. Take-Home Message •Multimodality imaging strategy, which integrates MRCA and IVUS, provides a viable solution to such clinical challenges, thereby enabling revascularization in patients with CAD with specific contraindications to conventional imaging. Multimodality imaging strategy, which integrates MRCA and IVUS, provides a viable solution to such clinical challenges, thereby enabling revascularization in patients with CAD with specific contraindications to conventional imaging. Past Medical History The patient's medical history was significant for hypertension, hyperlipidemia, and type 2 diabetes mellitus. Differential Diagnosis In addition to chest pain due to acute coronary syndrome (ACS) (potentially due to type 1, 2, or 4 myocardial infarction), other potential etiologies for presentation include myocardial injury due to Takotsubo cardiomyopathy, myocarditis, nonischemic myocardial injury, and noncardiac reasons for the symptoms. Investigations The patient was at high risk, and coronary revascularization should be performed. However, no coronary anatomic information was obtained owing to ICM-induced hypersensitivity reactions. Additionally, the use of gadolinium-based contrast agents posed a risk for further deterioration in renal function according to the abnormal renal function.1,2 After multidisciplinary team discussion involving cardiology, radiology, and nephrology, we proceeded with noncontrast magnetic resonance coronary angiography (MRCA) as the initial approach for coronary artery assessment. MRCA demonstrated a normal origin of the left and right coronary arteries, with a right-dominant coronary distribution. The right coronary artery (RCA) presented with a shepherd's hook morphology. No significant stenosis was observed in the RCA or the left circumflex coronary artery (LCx). However, a significant stenosis was identified in the proximal left anterior descending (LAD) artery (Figure 1). On the basis of the positive TET results, the lesion in the LAD was identified as the culprit lesion. It was decided to proceed with intravascular ultrasound (IVUS) to further evaluate coronary arteries and guide zero-contrast PCI. Magnetic Resonance Coronary Angiography Findings (A) Volume rendering image demonstrating normal coronary artery origin and distribution. (B) Maximum intensity projection of the RCA showing shepherd's hook morphology without significant stenosis. (C) Curved planar reformation revealing significant stenosis in the proximal LAD artery (red arrow). Magnetic resonance coronary angiography provided essential anatomic information without iodinated contrast or ionizing radiation. Dist = distal; LAD = left anterior descending; LCx = left circumflex coronary artery; Prox = proximal; RCA = right coronary artery. Management On the basis of preprocedural MRCA findings, the Sion blue guidewire course confirmed the assessment, and IVUS images revealed minimal lipid plaque in the RCA with no significant stenosis (Figure 2). The IVUS results further indicated the presence of fibrofatty plaques from the mid-LAD artery to the ostium (Figure 3). The most severe stenosis was located 8 mm from the LAD ostium, presenting as an ultrasound-attenuated plaque. The minimum lumen area was 2.25 mm2. The IVUS results indicated no significant stenosis in the LCx. After predilation with a 3 × 13-mm nonslip element balloon at 12 atm, IVUS guidance was used for optimal stent sizing and precise positioning. Two Promus Premier stents were implanted: one measuring 3 × 24 mm and the other 3.5 × 24-mm. These stents were placed extending from the LAD artery to the left main coronary artery (LMCA) with postdilation using both a 3 × 15-mm and a 3.5 × 15-mm noncompliant balloon at 18 to 20 atm. However, follow-up IVUS revealed a suboptimal stent area at the LAD ostium with associated malapposition in the LMCA. Subsequently, a 4 × 15 mm noncompliant balloon was inflated to 20 atm for postdilation at the LAD ostium, followed by proximal optimization technique using a 4.5 × 6-mm balloon at 14 atm in the LM (Figure 4). Repeat IVUS demonstrated satisfactory stent expansion and apposition, with minimum stent area of 6.74 mm2 in the distal LAD, 8.84 mm2 in the proximal LAD, and 15.42 mm2 in the LMCA. The LCx ostium was uncompromised (Figure 5). Postprocedural transthoracic echocardiography confirmed the absence of pericardial effusion. Right Coronary Artery Assessment (A) Fluoroscopic image confirming shepherd's hook morphology of the right coronary artery as predicted by magnetic resonance coronary angiography. (B) The cross-sectional image of intravascular ultrasound demonstrating minimal lipid-rich plaque without significant luminal narrowing, confirming the absence of flow-limiting stenosis. Left Anterior Descending Artery Lesion Characterization (A) Fluoroscopic image for the LAD artery. (B) Intravascular ultrasound longitudinal view demonstrating extensive fibrofatty plaque from mid-LAD artery to the ostium. The most severe stenosis (MLA 2.25 mm2) was located 8 mm from the LAD ostium, characterized by ultrasound-attenuated plaque suggesting lipid-rich composition. Diag = diagonal branch; LAD = left anterior descending; LCX = left circumflex coronary artery; MB = myocardial bridging; MLA = minimum lumen area; LMCA = left main coronary artery; Sep = septal branch. Detection and Correction of Left Main Coronary Artery Stent Malapposition (A) Postdeployment intravascular ultrasound revealing suboptimal stent expansion at the left anterior descending artery ostium with incomplete stent apposition in the left main coronary artery (red arrows indicate malapposed struts). (B) High-pressure postdilation using a 4 × 15-mm noncompliant balloon at 20 atm to optimize left anterior descending artery ostial stent expansion. (C) Proximal optimization technique performed with a 4.5 × 6-mm balloon at 14 atm to ensure complete left main coronary artery stent apposition. This sequence demonstrates the critical role of intravascular ultrasound in detecting and correcting suboptimal stent deployment without angiographic guidance. Final Intravascular Ultrasound Assessment Demonstrating Optimal Stent Results (A) Minimum stent area of 6.74 mm2 in the distal left anterior descending artery with complete stent expansion and apposition. (B) The stent area of 8.95 mm2 in the minimum lumen area site of the left anterior descending artery. (C) Minimum stent area of 8.84 mm2 in the proximal left anterior descending artery. (D) Minimum stent area of 15.42 mm2 in the left main coronary artery with excellent stent expansion. (E) Patent left circumflex coronary artery ostium without compromise, confirming preservation of side branch flow. All measurements met criteria for optimal stent deployment. Outcome and Follow-Up The patient remained hemodynamically stable postprocedure, with follow-up electrocardiography and transthoracic echocardiography showing no abnormalities. At the 1-month outpatient visit, he reported no chest pain recurrence, and a follow-up TET revealed no significant ischemia. The patient continued on guideline-directed secondary prevention medications for coronary artery disease (CAD). Discussion This case represents a unique clinical challenge: managing ACS in a patient with severe hypersensitivity reactions to ICM and completely unknown coronary anatomy. Although previous reports have demonstrated the feasibility of zero-contrast PCI under IVUS guidance,3,4 those patients had known coronary anatomy from previous images. In contrast, the present patient presented with no anatomic information, making conditions such as anomalous coronary origin or chronic total occlusion potential obstacles to successful IVUS-guided intervention. MRCA served as the critical “scout” in our strategy, providing essential anatomic information without iodinated contrast or ionizing radiation. With a sensitivity of 89% and specificity of 72% for diagnosing CAD,5 MRCA confirmed normal coronary origin and distribution, identified the right-dominant system with shepherd's hook RCA morphology, and precisely localized the culprit lesion to the proximal LAD artery. This anatomic roadmap was indispensable for planning the zero-contrast PCI. Recent technological advances including automated navigation, respiratory gating, and deep learning reconstruction have significantly improved MRCA image quality and efficiency,6 making it increasingly viable for clinical decision-making. IVUS functioned as an “intracorporeal microscope,” providing real-time, high-resolution assessment of vessel dimensions, plaque characteristics, and stent deployment.7 Under zero-contrast conditions, IVUS not only confirmed the severity of the proximal LAD lesion (minimum lumen area 2.25 mm2) but also guided optimal stent sizing, positioning, and postdeployment optimization. The detection of LMCA malapposition and subsequent successful correction with proximal optimization technique exemplifies the critical role of IVUS in ensuring procedural success without angiographic guidance. The synergy between MRCA and IVUS addresses the limitations of each modality. Although MRCA excels at visualizing proximal coronary anatomy and identifying significant stenoses, it has limited resolution for distal vessels and calcified lesions. IVUS provides precise intravascular assessment but requires a guidewire to reach the target lesion. By combining these complementary techniques, we achieved comprehensive evaluation and successful revascularization without any iodinated contrast, demonstrating a viable pathway for managing high-risk patients with absolute contraindications to conventional angiography. This approach has limitations. MRCA requires specialized equipment and expertise, and image quality can be affected by arrhythmias and patient cooperation. IVUS-guided PCI demands meticulous technique and experience, particularly in complex anatomies. Nevertheless, with continued technological advancement and growing operator experience, this multimodality imaging strategy holds promise as a standardized approach for patients with contrast contraindications requiring revascularization. Conclusions The successful management of this case demonstrates that the combined strategy of MRCA and IVUS-guided PCI represents a highly promising therapeutic approach for patients with CAD who have severe hypersensitivity reactions to ICM, particularly high-risk patients in need of revascularization. With continuous advancements in imaging technology and the accumulation of operator experience, this multimodality imaging strategy holds the potential to become a standardized pathway for addressing such clinical challenges, thereby enabling more patients with special conditions to benefit from revascularization therapy. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Equipment ListImaging•Magnetic resonance coronary angiography cardiac magnetic resonance 1.5 T system (Ambition; Philips Healthcare), equipped with a dedicated cardiac phased-array coil.•Intravascular ultrasound system (Boston Scientific)Access•6-F Glidesheath Slender (Terumo)•6-F EBU 3.5 guide catheter (Medtronic)•6-F JR 4 guide catheter (Medtronic)Percutaneous coronary intervention•Sion and Sion blue guidewire (ASAHI)•Nonslip element balloon 3 × 13 mm (Goodman)•Noncompliant (NC) Coronary Balloon Dilatation Catheter 3 × 15 mm (JW Medical Systems)•NC Quantum Maverick Balloon Catheter 3.5 × 15 mm (Boston Scientific)•NC Trek Coronary Dilatation Catheters 4 × 15 mm (Abbott)•Proximal optimization technique PTCA NC Balloon Dilatation Catheter 4.5 × 6mm (BrosMed)•Promus Premier verolimus-eluting platinum chromium coronary stents 3 × 24 mm and 3.5 × 24 mm (Boston Scientific) •Magnetic resonance coronary angiography cardiac magnetic resonance 1.5 T system (Ambition; Philips Healthcare), equipped with a dedicated cardiac phased-array coil. Magnetic resonance coronary angiography cardiac magnetic resonance 1.5 T system (Ambition; Philips Healthcare), equipped with a dedicated cardiac phased-array coil. •Intravascular ultrasound system (Boston Scientific) Intravascular ultrasound system (Boston Scientific) •6-F Glidesheath Slender (Terumo) 6-F Glidesheath Slender (Terumo) •6-F EBU 3.5 guide catheter (Medtronic) 6-F EBU 3.5 guide catheter (Medtronic) •6-F JR 4 guide catheter (Medtronic) 6-F JR 4 guide catheter (Medtronic) •Sion and Sion blue guidewire (ASAHI) Sion and Sion blue guidewire (ASAHI) •Nonslip element balloon 3 × 13 mm (Goodman) Nonslip element balloon 3 × 13 mm (Goodman) •Noncompliant (NC) Coronary Balloon Dilatation Catheter 3 × 15 mm (JW Medical Systems) Noncompliant (NC) Coronary Balloon Dilatation Catheter 3 × 15 mm (JW Medical Systems) •NC Quantum Maverick Balloon Catheter 3.5 × 15 mm (Boston Scientific) NC Quantum Maverick Balloon Catheter 3.5 × 15 mm (Boston Scientific) •NC Trek Coronary Dilatation Catheters 4 × 15 mm (Abbott) NC Trek Coronary Dilatation Catheters 4 × 15 mm (Abbott) •Proximal optimization technique PTCA NC Balloon Dilatation Catheter 4.5 × 6mm (BrosMed) Proximal optimization technique PTCA NC Balloon Dilatation Catheter 4.5 × 6mm (BrosMed) •Promus Premier verolimus-eluting platinum chromium coronary stents 3 × 24 mm and 3.5 × 24 mm (Boston Scientific) Promus Premier verolimus-eluting platinum chromium coronary stents 3 × 24 mm and 3.5 × 24 mm (Boston Scientific) Acknowledgments The authors acknowledge the support of the Department of Radiology at the First Affiliated Hospital of Xi'an Jiaotong University for providing technical support during the preparation of this case report. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References